診斷專業抗體市場 - 全球產業規模、佔有率、趨勢、機會和預測，按抗體、應用、最終用戶、地區和競爭細分，2020-2030 年預測

2024 年全球診斷專科抗體市值為 279.3 億美元，預計到 2030 年將達到 334.5 億美元，預測期內複合年成長率為 5.13%。全球診斷專科抗體市場是指用於診斷測試和檢測患者的特定疾病、病症或生物標記的專門抗體的市場。這些抗體是診斷檢測的重要組成部分，在準確、靈敏地檢測各種疾病和病症方面發揮著至關重要的作用。製藥和生物技術公司正在投資開發新型診斷檢測方法和特殊抗體，擴大市場供應。政府和醫療保健組織越來越關注預防性醫療保健措施，2022 年 1 月，Bio-Rad Laboratories, Inc. 推出了四種對帕妥珠單抗 (Perjeta) 表現出特殊特異性的抑制抗體。這些現成的抗體旨在阻止帕妥珠單抗與其標靶人類表皮生長因子 2 (HER2) 的結合，使研究人員能夠創建高度精確和敏感的檢測方法。這些檢測方法可用於診斷目的、生物分析以及製藥領域中帕妥珠單抗及其生物相似藥的監測。依賴特殊抗體的診斷測試對於識別患有慢性疾病風險的個體至關重要，從而實現預防干涉。全球老化人口更容易罹患慢性病。隨著老年人口的成長，對能夠解決與年齡相關的健康挑戰的診斷工具的需求也在增加。

主要市場促進因素

慢性病發生率上升

主要市場挑戰

開發和生產成本

主要市場趨勢

擴大即時診斷檢測

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球診斷特種抗體市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 按抗體（單株抗體、多株抗體、重組多多株抗體抗體）
  • 依應用（登革熱診斷、愛滋病毒診斷、肝炎診斷、傳染病診斷、腫瘤診斷、結核病診斷）
  • 按最終使用者（診斷實驗室、醫院、其他）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第 6 章：北美診斷特種抗體市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 加拿大
  • 墨西哥

第 7 章：歐洲診斷特種抗體市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 英國
  • 義大利
  • 法國
  • 西班牙

第 8 章：亞太地區診斷特種抗體市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 印度
  • 日本
  • 韓國
  • 澳洲

第 9 章：南美洲診斷特殊抗體市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲診斷特種抗體市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 科威特

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如果有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• F Hoffmann-La Roche Ltd
• Abcam Limited
• Abbott Laboratories Inc
• Bio-Rad Laboratories Inc
• Agilent Technologies Inc
• Creative Diagnostics
• Thermo Fisher Scientific Inc
• Becton Dickinson & Company
• Merck KGaA
• Sartorius AG

第 15 章：策略建議

第16章 關於出版商,免責事項

Global Diagnostic Specialty Antibodies Market was valued at USD 27.93 Billion in 2024 and is expected to reach USD 33.45 Billion by 2030 with a CAGR of 5.13% during the forecast period. The Global Diagnostic Specialty Antibodies Market refers to the market for specialized antibodies used in diagnostic tests and assays to detect specific diseases, conditions, or biomarkers in patients. These antibodies are crucial components of diagnostic assays and play a vital role in the accurate and sensitive detection of various diseases and conditions. Pharmaceutical and biotechnology companies are investing in the creation of novel diagnostic assays and specialty antibodies, expanding the market's offerings. Governments and healthcare organizations are increasingly focusing on preventive healthcare measures in January 2022, Bio-Rad Laboratories, Inc. introduced four inhibitory antibodies that exhibit exceptional specificity towards pertuzumab (Perjeta). These readily available antibodies are designed to impede the binding of pertuzumab to its target, the human epidermal growth factor 2 (HER2), thus enabling researchers to create highly precise and sensitive assays. These assays can be employed for diagnostic purposes, bioanalysis, and the monitoring of pertuzumab and its biosimilars in the realm of pharmaceuticals. Diagnostic tests that rely on specialty antibodies are essential for identifying individuals at risk of developing chronic diseases, enabling preventive interventions. The global aging population is more susceptible to chronic diseases. As the elderly population grows, so does the demand for diagnostic tools capable of addressing age-related health challenges.

Key Market Drivers

Rising Incidence of Chronic Diseases

The world is witnessing an alarming increase in the prevalence of chronic diseases, such as cancer, diabetes, cardiovascular disorders, and autoimmune conditions. This global health challenge has catalyzed a growing demand for precise and early diagnostic tools. In response, the Global Diagnostic Specialty Antibodies Market has emerged as a vital player in the healthcare sector. Chronic diseases have become a defining health issue of our time. In 2021, noncommunicable diseases (NCDs) were responsible for at least 43 million fatalities, accounting for 75% of global deaths unrelated to the pandemic. These conditions pose not only a significant threat to human health but also an economic burden on healthcare systems worldwide.

Diagnostic specialty antibodies, also known as immunoassays, are an integral part of modern diagnostic medicine. They are designed to detect specific biomarkers, antigens, or antibodies in patient samples, enabling accurate disease identification and monitoring. Chronic diseases are often asymptomatic in their early stages. Diagnostic specialty antibodies allow for the early detection of disease markers, facilitating timely interventions and treatment. This capability is crucial in improving patient outcomes and reducing the overall healthcare burden. The trend toward personalized medicine emphasizes treatments tailored to an individual's genetic makeup, lifestyle, and the specific characteristics of their disease. Diagnostic specialty antibodies play a pivotal role in identifying biomarkers that guide treatment decisions, ensuring that patients receive the most effective therapies. Many chronic diseases require ongoing monitoring to assess treatment efficacy and disease progression. Diagnostic specialty antibodies enable healthcare providers to track changes in biomarker levels, helping them make informed decisions about treatment adjustments. The increasing incidence of chronic diseases has prompted extensive research and development efforts in the field of diagnostics.

Early diagnosis of chronic diseases not only saves lives but also reduces the long-term healthcare costs associated with advanced disease management. Diagnostic specialty antibodies contribute significantly to this cost-saving aspect. Emerging economies in Asia-Pacific, Latin America, and Africa are experiencing rapid urbanization and improvements in healthcare infrastructure. This has led to increased access to diagnostic services and an expanding market for diagnostic specialty antibodies.

Key Market Challenges

Cost of Development and Production

The development and production of diagnostic specialty antibodies involve substantial financial investments, making cost a critical challenge in this market. The process begins with extensive research and development (R&D), where scientists identify and validate target antigens, followed by antibody generation, screening, and optimization. These initial stages require sophisticated laboratories, skilled personnel, and expensive reagents, significantly driving up costs. Producing high-quality, specific antibodies involves rigorous testing to ensure sensitivity, specificity, and reproducibility, further adding to the financial burden.

Manufacturing diagnostic specialty antibodies at scale demands advanced bioprocessing techniques, such as hybridoma technology or recombinant DNA methods, which require specialized equipment and stringent quality control measures. The purification and characterization of antibodies involve high costs due to the need for sophisticated chromatography systems and analytical tools. Good Manufacturing Practice (GMP) compliance adds another layer of cost, as regulatory agencies mandate strict quality assurance protocols throughout production.

These high production costs often translate into expensive end-user pricing, potentially restricting access to these essential diagnostic tools, especially in low- and middle-income countries with budget-constrained healthcare systems. the need for continuous innovation to enhance antibody performance further increases development expenses. Companies must balance investment in innovation with cost-effective production strategies to remain competitive while ensuring broader market accessibility. As a result, manufacturers are exploring alternative production approaches, such as plant-based antibody production and cell-free synthesis, to reduce costs and improve scalability. Despite these efforts, cost remains a significant barrier that impacts pricing, market expansion, and accessibility in the global diagnostic specialty antibodies market.

Key Market Trends

Expansion of Point-of-Care Testing

The expansion of point-of-care testing (POCT) is revolutionizing diagnostics by enabling rapid, decentralized testing that can be conducted at or near the patient's location. This shift reduces the dependency on centralized laboratories, facilitating quicker decision-making in clinical settings such as hospitals, physician offices, and even home-based care. POCT is particularly beneficial in emergency scenarios where immediate test results are necessary for timely medical interventions. Diagnostic specialty antibodies play a crucial role in POCT devices, as they are used in lateral flow assays, immunoassays, and other rapid detection platforms. The rising prevalence of infectious diseases, chronic conditions, and the demand for personalized healthcare are driving innovations in antibody-based POCT solutions. With ongoing advancements, POCT is expanding beyond conventional applications like glucose monitoring and pregnancy tests to more complex disease detection, including cardiac biomarkers, infectious disease screening, and oncology markers.

The growing focus on decentralized healthcare models, particularly in remote and resource-limited settings, is fueling the demand for rapid and reliable diagnostic solutions. The integration of POCT with digital health platforms and connectivity solutions enhances real-time monitoring and data sharing, improving patient outcomes and streamlining clinical workflows. The combination of artificial intelligence (AI) and POCT is also optimizing test interpretation, further driving the accuracy and efficiency of diagnostic specialty antibody-based assays.

As POCT continues to evolve, regulatory agencies are supporting its development through streamlined approval processes and quality assurance standards. Companies in the diagnostic specialty antibodies market are actively investing in research and development to enhance the sensitivity, specificity, and affordability of antibody-based POCT devices. In February 2022, Abcam and Twist Bioscience Corporation announced a licensing agreement under which Abcam will leverage Twist's proprietary VHH phage library for antibody discovery, development, and commercialization, with a focus on diagnostics and research applications. The continued expansion of POCT will significantly contribute to the growth of the global diagnostic specialty antibodies market, making diagnostics more accessible, efficient, and patient-centric.

Key Market Players

• F Hoffmann-La Roche Ltd
• Abcam Limited
• Abbott Laboratories Inc
• Bio-Rad Laboratories Inc
• Agilent Technologies Inc
• Creative Diagnostics
• Thermo Fisher Scientific Inc
• Becton Dickinson & Company
• Merck KGaA
• Sartorius AG

Report Scope:

In this report, the Global Diagnostic Specialty Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Diagnostic Specialty Antibodies Market, By Antibody:

• Monoclonal Antibodies
• Polyclonal Antibodies
• Recombinant Polyclonal Antibodies

Diagnostic Specialty Antibodies Market, By Application:

• Dengue Diagnostics
• HIV Diagnostics
• Hepatitis Diagnosis
• Infectious Disease Diagnostics
• Oncology Diagnostics
• Tuberculosis Diagnostics

Diagnostic Specialty Antibodies Market, By End User:

• Diagnostic Laboratories
• Hospitals
• Others

Diagnostic Specialty Antibodies Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Diagnostic Specialty Antibodies Market.

Available Customizations:

Global Diagnostic Specialty Antibodies market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Diagnostic Specialty Antibodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Antibody (Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Polyclonal Antibodies)
  • 5.2.2. By Application (Dengue Diagnostics, HIV Diagnostics, Hepatitis Diagnosis, Infectious Disease Diagnostics, Oncology Diagnostics, Tuberculosis Diagnostics)
  • 5.2.3. By End User (Diagnostic Laboratories, Hospitals, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Diagnostic Specialty Antibodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Antibody
  • 6.2.2. By Application
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Diagnostic Specialty Antibodies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Antibody
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Diagnostic Specialty Antibodies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Antibody
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Diagnostic Specialty Antibodies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Antibody
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By End User

7. Europe Diagnostic Specialty Antibodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Antibody
  • 7.2.2. By Application
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Diagnostic Specialty Antibodies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Antibody
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By End User
  • 7.3.2. United Kingdom Diagnostic Specialty Antibodies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Antibody
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By End User
  • 7.3.3. Italy Diagnostic Specialty Antibodies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Antibody
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By End User
  • 7.3.4. France Diagnostic Specialty Antibodies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Antibody
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Diagnostic Specialty Antibodies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Antibody
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By End User

8. Asia-Pacific Diagnostic Specialty Antibodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Antibody
  • 8.2.2. By Application
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Diagnostic Specialty Antibodies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Antibody
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By End User
  • 8.3.2. India Diagnostic Specialty Antibodies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Antibody
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Diagnostic Specialty Antibodies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Antibody
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Diagnostic Specialty Antibodies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Antibody
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Diagnostic Specialty Antibodies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Antibody
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By End User

9. South America Diagnostic Specialty Antibodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Antibody
  • 9.2.2. By Application
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Diagnostic Specialty Antibodies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Antibody
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Diagnostic Specialty Antibodies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Antibody
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Diagnostic Specialty Antibodies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Antibody
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By End User

10. Middle East and Africa Diagnostic Specialty Antibodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Antibody
  • 10.2.2. By Application
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Diagnostic Specialty Antibodies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Antibody
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Diagnostic Specialty Antibodies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Antibody
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Diagnostic Specialty Antibodies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Antibody
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By End User
  • 10.3.4. Kuwait Diagnostic Specialty Antibodies Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Antibody
      • 10.3.4.2.2. By Application
      • 10.3.4.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. F Hoffmann-La Roche Ltd
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Abcam Limited
• 14.3. Abbott Laboratories Inc
• 14.4. Bio-Rad Laboratories Inc
• 14.5. Agilent Technologies Inc
• 14.6. Creative Diagnostics
• 14.7. Thermo Fisher Scientific Inc
• 14.8. Becton Dickinson & Company
• 14.9. Merck KGaA
• 14.10. Sartorius AG

15. Strategic Recommendations

16. About Us & Disclaimer